Browse by Series:

Combining BRAF, MEK and EGFR Inhibition in mCRC

Insights From: Scott Kopetz, MD, PhD, FACP, The University of Texas MD Anderson Cancer Center; Ryan Corcoran, MD, PhD, Massachusetts General Hospital Cancer Center
Published: Thursday, Jan 31, 2019



Experts review the scientific rationale for combining BRAF, MEK and EGFR inhibition in BRAF-mutated mCRC; a strategy tested in such settings as the ANCHOR and BEACON trials.
SELECTED
LANGUAGE
Slider Left
Slider Right


Experts review the scientific rationale for combining BRAF, MEK and EGFR inhibition in BRAF-mutated mCRC; a strategy tested in such settings as the ANCHOR and BEACON trials.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x